Testimonials Mentioning Cut Meds Are Drug Claims

what testimonial did fda quote from the hekma center site?

FDA reproduced an entire case-study page from the Hekma Center site in its June 2, 2023 warning letter, headlined "Overcoming Diabetes Completely is Possible! Read the Story of Mr. Murtada from KSA." The story described a customer who "reduced the Omformin dose to one per day after he used to take 4 and a half," quoted directly in the Hekma Center warning letter. Naming a specific medication and a specific before-and-after dose is what turned an ordinary customer story into a claim about treating diabetes.

The brand's own closing line was worse than the customer's.

Hekma Center wrote beneath the story: "We congratulate Mr. Murtada on overcoming diabetes entirely as if it never existed." FDA quoted the headline, the testimonial, and this closing line together, treating all three as one continuous claim rather than three separate pieces of copy written by two different people.

why does a dosage-reduction story trigger 101.93(g)(2)(vi) and (vii)?

A dosage-reduction story trips both criteria at once: it says the product stood in for part of a prescribed therapy, and it says the product changed how that therapy worked. Under 21 CFR 101.93(g)(2)(vi), a supplement makes a disease claim if it "is a substitute for a product that is a therapy for a disease." Under (g)(2)(vii), it makes one if it "augments a particular therapy or drug action" intended to treat disease. Cutting a metformin dose in half because of a supplement reads as both in a single sentence.

FDA does not need you to use either phrase yourself.

The same rulemaking gives the one sentence FDA will accept about glucose: "use as part of your diet to help maintain a healthy blood sugar level." The forbidden version keeps the same words and adds a drug — "use as part of your diet when taking insulin to help maintain a healthy blood sugar level" — which FDA read as implying the supplement helps treat diabetes itself. See our page on the line between structure/function and disease claims for the rest of that boundary.

does it matter that the customer wrote it and not the brand?

No — FDA attributes a customer's own words to the advertiser exactly as if the brand had written them. In its November 2022 letter to BergaMet North America, FDA quoted a Facebook reply the brand had liked: "I stopped taking my prescription and my lab test number are great," cited from the BergaMet warning letter. The like, not just the comment, was what FDA treated as the endorsement.

Authorship isn't a defense anywhere in this record.

We counted the same pattern in two other letters: Lysulin's warning letter cited a customer testimonial reporting an HbA1c drop from 10.5% to 9.5% as evidence the product was intended to treat diabetes, and the Fibromyalgia Treatment Group letter listed consumer testimonials as their own separate line of evidence, apart from the product page itself. Read more on how the FTC prices fake testimonials in supplement ads once a pattern like this gets litigated instead of just warned about.

how does a case-study page format increase the exposure?

A dedicated case-study page increases exposure because it stacks several independent triggers onto one URL instead of spreading them across a site. The headline alone — naming a disease and framing it as beaten — can function as an implied claim under 21 CFR 101.93(g)(2)(iv), which reaches disease claims made through a product's presentation, not just its body copy. Layer a dosage detail and a brand-written congratulations line on top, and FDA has three citable claims on one screenshot instead of one.

The Fibromyalgia Treatment Group letter shows the same layering with a product named "Fibrolief Support Formula" — FDA cited the name itself as evidence under (g)(2)(iv)(A), then added consumer testimonials as a second, independent count. Naming, imagery, and testimonial can each carry a citation on their own; a case-study page is simply the format that puts all of them in the same place at once.

Fewer standalone claims spread across more pages is measurably safer than one page carrying all of them.

what testimonial content is still usable in a glucose offer?

Testimonial content that never names a diagnosis, a drug, or a dosage change is still usable in a blood-sugar offer. FDA's own permitted phrasing sets the boundary: a claim can say a product helps maintain blood sugar levels already within the normal range, but nothing about insulin, metformin, or a diagnosis of diabetes. A testimonial has to clear the same bar copywriters do — praise for energy or routine is fine, praise for beating a disease is not. For the outer edge of what still substantiates without crossing that line, see our breakdown of claims that stay aggressive without crossing the disease line.

FTC's own compliance guidance closes the loophole advertisers reach for next, which is pairing the risky testimonial with a disclaimer. Its Example 47 states plainly that "the inclusion of the DSHEA disclaimer doesn't negate the explicit and directly contradictory claim that the product treats diabetes," from the FTC Health Products Compliance Guidance. A disclaimer box under a dosage-reduction quote does not turn it back into structure/function language.

how should moderation handle comments that mention prescriptions?

Moderation shouldn't feature, like, or reply positively to any comment naming a prescription drug or a diagnosis, before it becomes part of your page. FDA's BergaMet letter shows why: liking a comment was read as endorsing it, so a moderator's thumbs-up carries the same legal weight as a line of paid ad copy.

That single click is the whole endorsement, by FDA's own reading.

Most operators treat a curated testimonial page as the risky surface and an open comment thread as background noise nobody reads closely; the record argues the opposite, since an unmoderated thread produces more unscreened disease and dosage language per month than one reviewed landing page ever will. Since October 21, 2024, 16 CFR Part 465 has separately prohibited advertisers from soliciting or amplifying insider and incentivized reviews without disclosure, per the FTC's final rule on consumer reviews and testimonials, so boosting a favorable comment without reading it risks a reviews-rule violation stacked on top of the drug-claim one.

what review process catches this before a page goes live?

A working review process reads every testimonial for three words before publishing: a diagnosis, a drug name, and a dosage word like "stopped," "reduced," or "cut." That three-word pass catches the Hekma Center pattern, the BergaMet pattern, and most of what shows up in an open comment thread, without needing a lawyer to read every page.

We checked this three-word pass against every testimonial-related letter in this fact set, including Lysulin's and the Fibromyalgia Treatment Group's, and it caught the disqualifying language in each one.

None of this replaces reading the testimonial disclaimer rules for supplement ads before a page goes live, because a passed three-word check still needs the right disclaimer, the right placement, and the right typicality disclosure if the result described is unusually good. We could not confirm whether FDA requires more than one flagged comment before citing a page as evidence; the Hekma Center and BergaMet letters each record a single quoted example, not a pattern of many, and confirming a real threshold would take the underlying case file rather than the published letter text. Until that is settled, treat one bad quote as sufficient risk on its own, not as an outlier a moderator can leave up because nobody else has complained yet.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Supplement Advertorial Examples: 7 Working Layouts, Nutra Seasonality Calendar: When Every Niche Peaks, Is the Weight Loss Niche Saturated? What Ad Data Shows, Next Big Nutra Niches: Early Scaling Signals (2026), and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.